EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort –
Covered in this story
What has happened since
- Advanced Micro Devices is up 0.4% since this was published, 66 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Advanced Micro Devices
- Bank of America: $606 → $720 by Oct 2027 · Buy via FXLeaders
- UBS: $608 → $700 by Oct 2027 · Buy via Stocktwits
- Rosenblatt Securities: $608 → $665 by Oct 2027 · Buy via Stocktwits
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Advanced Micro Devices →Dalsna Finance is currently tracking 55 stories mentioning Advanced Micro Devices, the earliest published 4 Aug 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.